Cyclophos - (500 mg/2.5 mL and 1 g/5 mL ; Solution, Intravenous)

Generic Name	Cyclophosphamide	Innovator	Ingenus pharma
Dosage	500 mg/2.5 mL and 1 g/5 mL ; Solution, Intravenous	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Cyclophosphamide is an alkylating drug indicated for treatment of Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
***** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** **, ****
****** (*****)	** \ **	*** **, ****	*******	****	*** ****** *** ****
******	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events

Cyclophos - (2 g/10 mL; Solution, Intravenous)

Generic Name	Cyclophosphamide	Innovator	Ingenus pharma
Dosage	2 g/10 mL; Solution, Intravenous	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Cyclophosphamide is an alkylating drug indicated for treatment of Malignant Diseases (malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma).
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** (*****)	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
******	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events